藥學前沿大講堂第125講-DNA topoisomerase I inhibitors: from bench to bedside
DNA topoisomerase I inhibitors: from bench to bedside
題 目：DNA topoisomerase I inhibitors: from bench to bedside
報告人：Yves Pommier, M.D., Ph.D.
Chief, Laboratory of Molecular Pharmacology, Center for Cancer Research,
National Cancer Institute, NIH, USA
主持人：古練權 教授 太阳集团1088vip
時 間：
地 點：中山大學東校區太阳集团1088vip 125講學廳
報告人介紹：
Dr. Pommier received his M.D. and Ph.D. degrees from University of Paris in 1981 and 1986, respectively. He has been at the NIH since 1981. He is the Chief of the Laboratory of Molecular Pharmacology, co-Chair of the Discovery Committee of the NCI Experimental Therapeutics Program and member of the Molecular Target steering committee at the NCI-Center for Cancer Research. He has received an NIH Merit Award for his role in elucidating the function of topoisomerases as targets for anticancer drugs and several Federal Technology Transfer Awards for his discoveries of HIV-1 integrase and DNA topoisomerase inhibitors. He serves as Senior Editor for Cancer Research, Therapeutics, Targets, and Chemical Biology section. Dr. Pommier received the “Paul Ehrlich lecture award” from the Societé de Chinie Thérapeutique in 2005. He has authored over 500 publications and holds over 20 patents for inhibitors of DNA topoisomerases, Tyrosyl-DNA phosphodiesterase, checkpoint inhibitors and HIV-1 integrase inhibitors.
歡迎廣大師生踴躍參加！